Metronidazole (Paediatric)
Brand names: Flagyl, Metronidazole Suspension
Metronidazole (paediatric) is an antimicrobial used in children for anaerobic bacterial infections and certain protozoal infections, including intra-abdominal and dental infections, C. difficile and giardiasis. This page covers its use in the paediatric population.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Within susceptible anaerobic bacteria and protozoa it is reduced to reactive intermediates that damage microbial DNA, leading to cell death.
Prescribing in practice
- The most important paediatric counselling point is that alcohol (including in liquid medicines and some mouthwashes) must be avoided during and shortly after treatment because of a disulfiram-like reaction.
- Prolonged or repeated courses carry a risk of peripheral and central neurotoxicity, so duration should be limited and the indication reviewed.
- Dose is weight-based and available by oral, intravenous and rectal routes; doses should be confirmed against a children's formulary, with caution in hepatic impairment.
Monitoring
Monitor for neurological symptoms (numbness, tingling, ataxia) and hepatic function on prolonged courses, alongside clinical response.
Counselling the patient
- Avoid all alcohol during the course and for a short period afterwards to prevent flushing, nausea and palpitations.
- Report any numbness, tingling, unsteadiness or persistent headache.
- Complete the full course as prescribed even if the child feels better.
Evidence & guidelines
Metronidazole is a long-established first-line agent for anaerobic and several protozoal infections, with its alcohol interaction and neurotoxicity risk well documented.
Reference: NICE NG199 (C. difficile); PHE Antibiotic Guidelines; IDSA/SHEA C. difficile Guidelines 2021; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- PICU Delirium Assessment (pCAM-ICU) · Delirium Assessment
- Vasoactive-Inotropic Score (VIS) · Inotropic Support
- Lund-Browder Chart — TBSA Burn Estimation · Burns
- Centor/McIsaac Score (Pharyngitis) · Throat Infections
- IE Prophylaxis Indication · Treatment
- Kocher Criteria for Septic Arthritis · Bone & Joint Infection